Cycloastragenol prevents age-related bone loss: Evidence in d-galactose-treated and aged rats

作者：Yongjie Yu, Jingkai Wu, Jin Li, Yanzhi Liu, Yanzhi Liu, Xiaoyan Zheng, Mingzhu Du, Limin Zhou, Yajun Yang, Shiying Luo, Wenjia Hu, Lin Li, Weimin Yao, Yuyu Liu, Yuyu Liu · 发表于：Biomedicine & Pharmacotherapy · 年份：2020 · DOI：10.1016/j.biopha.2020.110304 · 被引用次数：41 · 研究领域：Bone Metabolism and Diseases、Telomeres, Telomerase, and Senescence、Antioxidants, Aging, Portulaca oleracea

BACKGROUND AND AIMS: Aging-induced bone loss is a multifactorial, age-related, and progressive phenomenon among the general population and may further progress to osteoporosis and increase the risk of fractures. Cycloastragenol (CAG), currently the only compound reported that activates human telomerase, is thought to be able to alleviate or delay the symptoms of aging and chronic diseases. Previous research has suggested that CAG may have the potential to alleviate age-related bone loss. However, to date, no research has specifically focused on this aspect. In this study, we aimed to investigate whether CAG could prevent senile osteoporosis, and further reveal its underlying mechanism. METHODS: CAG treatment was administrated into two bone loss rat models (D-galactose administration and aging) for 20 weeks and 33 weeks, respectively. Serum biomarkers analyses, bone biomechanical tests, micro-computed tomography assessment, and bone histomorphometry analyses were performed on the bone samples collected at the endpoint, to determine whether CAG could prevent or alleviate age-related bone loss. Proteomic analysis was performed to reveal the changes in protein profiles of the bones, and western blot was used to further verify the identity of the key proteins. The viability, osteoblastic differentiation, and mineralization of MC3T3-E1 cells were also evaluated after CAG treatment in vitro. RESULTS: The results suggest that CAG treatment improves bone formation, reduces osteoclast ...